Presentation
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides).
Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome’s Mimicry drug discovery platform uses best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million full-length gut microbiome proteins. This platform is highly productive and has already generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.
Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones or cytokines. The Company is presently advancing its proprietary OncoMimics™ pipeline of distinct drug candidates – EO2401 in glioblastoma and adrenal tumors, EO2463 in indolent non-Hodgkin lymphomas, EO2040 in colorectal cancer with ctDNA-defined, minimal residual disease and EO4010 for third-line colorectal cancer.
Contact
Address
94-96 Avenue Ledru Rollin, 75011 Paris
Website
Targeted indications : Breast cancer, Brain cancer, Gastrointestinal cancers, Hematologic cancer